Manish R. Sharma

Also affiliated with South Texas Accelerated Research Therapeutics, Start Treatment & Recovery Centers

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 3 papers. Top paper: “SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy”.

SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

Cancer Discovery(2023)10.1158/2159-8290.cd-23-0361

N/A

0.639DataRank · unranked

70 citations

Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish M. Gadgeel, Dale Nepert +20 more

Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies

Journal of Hematology & Oncology(2025)10.1186/s13045-025-01705-2

N/A

0.477DataRank · unranked

23 citations

Jordi Rodon, Yan Liang, Xinhong Wu, Qun Li, Lihua Song +23 more

Data from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

(2023)10.1158/2159-8290.c.6679570

N/A

0DataRank · unranked

0 citations

Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish M. Gadgeel, Dale Nepert +20 more